Kezar Life Sciences
KZR was delisted on the 8th of May, 2026.
78 hedge funds and large institutions have $109M invested in Kezar Life Sciences in 2020 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 29 increasing their positions, 27 reducing their positions, and 17 closing their positions.
5,200% more call options, than puts
Call options by funds: $53K | Put options by funds: $1K
7% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 27
0.06% less ownership
Funds ownership: 5.07% → 5.01% (-0.06%)
7% less capital invested
Capital invested by funds: $117M → $109M (-$7.94M)
8% less funds holding
Funds holding: 85 → 78 (-7)
41% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 17
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$3.24M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
+$1.75M |
| 3 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$1.39M |
| 4 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$1.39M |
| 5 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$1.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$1.76M |
| 2 |
LM
Luminus Management
Houston,
Texas
|
-$1.34M |
| 3 |
Millennium Management
New York
|
-$994K |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$932K |
| 5 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$777K |
KZR Hedge Fund Activity: Q3 2020 in Review
78 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Kezar Life Sciences (KZR) for Q3 2020, worth a combined $109M — down 6.8% from $117M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of KZR and 10 opened new positions — a net loss of 7 holders — while 27 trimmed existing stakes and 29 added.
The largest buyer was Opaleye Management, opening a new position worth an estimated $3.24M. The largest seller was Cormorant Asset Management, cutting an estimated $1.76M.
- 78 institutional investors held Kezar Life Sciences (KZR) as of Q3 2020, down from 85 in Q2 2020.
- Funds reported $109M of Kezar Life Sciences stock for Q3 2020, down 6.8% quarter-over-quarter.
- 10 funds opened new Kezar Life Sciences positions in Q3 2020 and 17 closed out, a net change of -7 holders.
- The largest Kezar Life Sciences buyer in Q3 2020 was Opaleye Management, an estimated $3.24M added.
- The largest Kezar Life Sciences seller in Q3 2020 was Cormorant Asset Management, an estimated $1.76M sold.
Based on aggregated 13F filings for Q3 2020.